Cover Image
市場調查報告書

大腸癌診斷檢驗的全球市場:醫療設備的開發平台評估

Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

出版商 GlobalData 商品編碼 366599
出版日期 內容資訊 英文 358 Pages
訂單完成後即時交付
價格
Back to Top
大腸癌診斷檢驗的全球市場:醫療設備的開發平台評估 Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017
出版日期: 2017年10月01日 內容資訊: 英文 358 Pages
簡介

本報告提供全球大腸癌診斷檢驗相關產品市場上的主要開發中產品及其臨床實驗的進展調查,再彙整產品功能·特性比較分析 (臨床實驗的各進展階段) ,與主要企業簡介及代表性產品,近來的市場動靜 (業績報告·資本交易趨勢等) 資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 大腸癌診斷檢驗概要

第3章 臨床實驗中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各領域
  • 開發中產品:各法規途徑
  • 開發中產品:各估計認證時期
  • 開發中產品:現在進行中的臨床實驗

第4章 臨床實驗中的開發中產品:各企業

  • 大腸癌診斷檢驗的企業:各臨床實驗階段的開發中產品
  • 大腸癌診斷檢驗:各臨床實驗階段的開發中產品

第5章 大腸癌診斷檢驗市場:企業·產品概要 (全119公司份)

  • A2K Technologies
  • Abbott Diagnostics
  • Abcodia Ltd.
  • Acobiom
  • Advanced Marker Discovery, S.L.
  • Advpharma Inc.
  • Ambergen, Inc.
  • Ambrilia Biopharma Inc.
  • Arizona State University
  • ArtemixRx
  • Asuragen, Inc.
  • Bio Mark Ltd
  • Biocartis SA
  • Biodesix Inc.
  • BioMarCare Technologies Ltd.
  • BioMark Diagnostics Inc.
  • BioMarker Strategies, LLC
  • bioMerieux S.A.
  • Biomoda, Inc. (Inactive)
  • Biosceptre (Aust) Pty Ltd
  • BioSystems International
  • Biotechnostics GmbH
  • BioTime, Inc.
  • Biotron Limited
  • Castle Biosciences Incorporated
  • Cellmid Limited
  • Ceres Nanosciences, Inc.
  • Cernostics Inc.
  • China Sky One Medical, Inc.
  • Chronix Biomedical, Inc.
  • Cleveland Diagnostics Inc.
  • ColoPrev
  • Columbia University
  • Courtagen Life Sciences, Inc.
  • CS-Keys, Inc.
  • Di.V.A.L Toscana srl
  • Diadexus Inc
  • DiagnoCure Inc.
  • Diaxonhit S.A.
  • EDP Biotech Corporation
  • Epigenomics AG
  • Eventus Diagnostics, Inc.
  • Exact Sciences Corporation
  • Exiqon A/S
  • Exosomics Siena SpA
  • Fina Biotech
  • GenomicTree, Inc.
  • Ghent University
  • GlycoZym
  • Health Discovery Corporation
  • Human Metabolome Technologies, Inc.
  • Ikonisys, Inc.
  • InterGenetics Incorporated
  • IV Diagnostics, Inc.
  • John Hopkins University
  • Lab21 Limited
  • Laboratorios Alpha San Ignacio Pharma S.L.
  • Lightsphere Diagnostics
  • LX Diagnostics
  • MabCure Inc.
  • Matrix-Bio, Inc.
  • Max-Delbruck-Centrum fur Molekulare Medizin (MDC)
  • MDNA Life Sciences, Inc.
  • MDxHealth SA
  • Merrimack Pharmaceuticals, Inc.
  • Metabiomics Corporation
  • Metabolomic Technologies Inc.
  • Metabolon, Inc.
  • MetaStat, Inc.
  • Milagen, Inc.
  • Miraculins Inc.
  • Mode Dx Ltd.
  • Moscow Institute of Physics and Technology
  • Myriad Genetics, Inc.
  • Nanosphere, Inc.
  • NetScientific Plc
  • Norda ASA
  • Novel Bio-spectrum Technologies, Inc.
  • Nuclea Biotechnologies Inc.
  • Nuvera Biosciences, Inc.
  • Oncimmune (USA) LLC
  • OncoVista Innovative Therapies, Inc.
  • On-Q-ity, Inc. (Inactive)
  • Origin Sciences Limited
  • Orion Genomics LLC
  • OTraces Inc.
  • Oxford Cancer Biomarkers
  • Oxford Gene Technology Limited
  • Panacea Pharmaceuticals, Inc.
  • PleX Diagnostics
  • Precision Biologics, Inc.
  • Prediction Sciences
  • Protagen AG
  • Rabin Medical Center
  • Rosetta Genomics Ltd
  • Scienion AG
  • Seegene, Inc.
  • Shuwen Biotech Co. Ltd.
  • Siamab Therapeutics, Inc.
  • Skuldtech France
  • Sysmex
  • Tel Aviv University
  • The Chinese University of Hong Kong
  • The Walter and Eliza Hall Institute of Medical Research
  • TheraDiag SA
  • Theranostics Health, Inc.
  • Todos Medical Company Overview
  • Universal Diagnostics, S. L.
  • Universite De Lyon
  • University of Alabama at Birmingham
  • University of Illinois at Chicago
  • University of Texas at Austin
  • US Biomarkers, Inc.
  • Vanderbilt University
  • Vermillion, Inc.
  • Viomics Inc.
  • Vitatex Inc.
  • VolitionRX Ltd.
  • XEPTAGEN SpA

第6章 大腸癌診斷檢驗市場市場:目前的趨勢 (全99件)

第7章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0454EPD

GlobalData's Medical Devices sector report, "Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Colorectal Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Colorectal Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Colorectal Cancer Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Colorectal Cancer Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Colorectal Cancer Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 9
  • 1.2 List of Figures 17

2 Introduction 18

  • 2.1 Colorectal Cancer Diagnostic Tests Overview 18

3 Products under Development 19

  • 3.1 Colorectal Cancer Diagnostic Tests - Pipeline Products by Stage of Development 19
  • 3.2 Colorectal Cancer Diagnostic Tests - Pipeline Products by Territory 20
  • 3.3 Colorectal Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 21
  • 3.4 Colorectal Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 22
  • 3.5 Colorectal Cancer Diagnostic Tests - Ongoing Clinical Trials 23

4 Colorectal Cancer Diagnostic Tests - Pipeline Products under Development by Companies 24

  • 4.1 Colorectal Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 24
  • 4.2 Colorectal Cancer Diagnostic Tests - Pipeline Products by Stage of Development 29

5 Colorectal Cancer Diagnostic Tests Companies and Product Overview 33

  • 5.1 Abcodia Ltd Company Overview 33
  • 5.2 Advanced Marker Discovery SL Company Overview 34
  • 5.3 Advpharma Inc Company Overview 35
  • 5.4 Almac Diagnostics Ltd Company Overview 36
  • 5.5 Ambergen Inc Company Overview 37
  • 5.6 Applied Proteomics Inc Company Overview 38
  • 5.7 Arizona State University Company Overview 39
  • 5.8 ArtemixRx Company Overview 40
  • 5.9 Avant Diagnostics, Inc. Company Overview 41
  • 5.10 Bio Mark Ltd Company Overview 42
  • 5.11 Biocartis SA Company Overview 43
  • 5.12 Biodesix Inc Company Overview 44
  • 5.13 BioMarCare Technologies Ltd. Company Overview 45
  • 5.14 BioMark Diagnostics Inc. Company Overview 47
  • 5.15 BioMarker Strategies LLC Company Overview 48
  • 5.16 bioMerieux S.A. Company Overview 49
  • 5.17 Biomoda, Inc. (Inactive) Company Overview 50
  • 5.18 Bioprognos SL Company Overview 51
  • 5.19 Biosceptre International Ltd Company Overview 52
  • 5.20 BioSystems International Company Overview 53
  • 5.21 BioTime Inc Company Overview 54
  • 5.22 Biotron Ltd Company Overview 55
  • 5.23 Castle Biosciences Inc Company Overview 56
  • 5.24 Catholic University of Leuven Company Overview 57
  • 5.25 Cellmid Ltd Company Overview 58
  • 5.26 Ceres Nanosciences Inc Company Overview 60
  • 5.27 Cernostics Inc. Company Overview 61
  • 5.28 China Sky One Medical Inc Company Overview 62
  • 5.29 Chinese University of Hong Kong Company Overview 63
  • 5.30 Chronix Biomedical Inc Company Overview 65
  • 5.31 Columbia University Company Overview 66
  • 5.32 Courtagen Life Sciences Inc Company Overview 67
  • 5.33 CS-Keys, Inc. (Inactive) Company Overview 68
  • 5.34 Di.V.A.L Toscana srl Company Overview 69
  • 5.35 DiagnoCure Inc. (Inactive) Company Overview 70
  • 5.36 Diaxonhit SA Company Overview 72
  • 5.37 Diazyme Laboratories Inc Company Overview 73
  • 5.38 DNAlytics Company Overview 74
  • 5.39 EDP Biotech Corporation Company Overview 77
  • 5.40 Epigenomics AG Company Overview 78
  • 5.41 Eventus Diagnostics Inc (Inactive) Company Overview 80
  • 5.42 Exact Sciences Corp Company Overview 81
  • 5.43 Exiqon A/S Company Overview 82
  • 5.44 Exosomics Siena SpA Company Overview 83
  • 5.45 Fina Biotech SL Company Overview 84
  • 5.46 GenomicTree Inc Company Overview 85
  • 5.47 German Cancer Research Center Company Overview 89
  • 5.48 Ghent University Company Overview 91
  • 5.49 GlycoZym Company Overview 92
  • 5.50 Health Discovery Corp Company Overview 93
  • 5.51 Human Metabolome Technologies Inc Company Overview 94
  • 5.52 Ikonisys Inc Company Overview 95
  • 5.53 InterGenetics Inc Company Overview 96
  • 5.54 IV Diagnostics, Inc. Company Overview 97
  • 5.55 John Hopkins University Company Overview 98
  • 5.56 King Abdullah University of Science and Technology Company Overview 100
  • 5.57 Kyo Diagnostics KK Company Overview 101
  • 5.58 Lab21 Ltd Company Overview 102
  • 5.59 Laboratorios Alpha San Ignacio Pharma S.L. Company Overview 103
  • 5.60 Leitat Technological Center Company Overview 104
  • 5.61 Lightsphere Diagnostics Company Overview 106
  • 5.62 Luminor Medical Technologies Inc Company Overview 107
  • 5.63 LX Diagnostics Company Overview 108
  • 5.64 MabCure Inc. Company Overview 109
  • 5.65 Master Diagnostica Sociedad Limitada Company Overview 110
  • 5.66 Matrix-Bio, Inc. Company Overview 111
  • 5.67 Max-Delbruck-Centrum fur Molekulare Medizin (MDC) Company Overview 114
  • 5.68 MDNA Life Sciences Inc Company Overview 115
  • 5.69 MDxHealth SA Company Overview 116
  • 5.70 Merrimack Pharmaceuticals Inc Company Overview 118
  • 5.71 Metabiomics Corporation Company Overview 119
  • 5.72 Metabolomic Technologies Inc Company Overview 121
  • 5.73 Metabolon Inc Company Overview 122
  • 5.74 MetaStat Inc Company Overview 123
  • 5.75 Milagen Inc Company Overview 124
  • 5.76 Mode Dx Ltd. Company Overview 125
  • 5.77 Myriad Genetics Inc Company Overview 126
  • 5.78 Nanocytomics LLC Company Overview 127
  • 5.79 Norda ASA Company Overview 128
  • 5.80 Novel Bio-spectrum Technologies Inc (Inactive) Company Overview 129
  • 5.81 Nuclea Biotechnologies Inc. (Inactive) Company Overview 130
  • 5.82 Oncimmune (USA) LLC Company Overview 131
  • 5.83 Onconome, Inc. (Inactive) Company Overview 132
  • 5.84 OncoStem Diagnostics Pvt. Ltd Company Overview 133
  • 5.85 OncoVista Innovative Therapies Inc Company Overview 134
  • 5.86 On-Q-ity, Inc. (Inactive) Company Overview 135
  • 5.87 Origin Sciences Limited Company Overview 136
  • 5.88 Orion Genomics LLC Company Overview 137
  • 5.89 OTraces Inc. Company Overview 138
  • 5.90 Oxford Cancer Biomarkers Company Overview 139
  • 5.91 Oxford Gene Technology Ltd Company Overview 141
  • 5.92 PleX Diagnostics Inc (Inactive) Company Overview 142
  • 5.93 Precision Biologics Inc Company Overview 143
  • 5.94 Prediction Sciences LLC (Inactive) Company Overview 146
  • 5.95 PreMD Inc (Inactive) Company Overview 147
  • 5.96 Protagen AG Company Overview 148
  • 5.97 Protein Alternatives SL Company Overview 149
  • 5.98 Quest Diagnostics Inc Company Overview 150
  • 5.99 Rabin Medical Center Company Overview 151
  • 5.100 Rna Diagnostics Inc. Company Overview 152
  • 5.101 Rosetta Genomics Ltd Company Overview 153
  • 5.102 Scienion AG Company Overview 154
  • 5.103 Seegene Inc Company Overview 155
  • 5.104 Shuwen Biotech Co Ltd Company Overview 156
  • 5.105 Siamab Therapeutics Inc Company Overview 157
  • 5.106 Skuldtech France Company Overview 158
  • 5.107 Sysmex Corp Company Overview 159
  • 5.108 Tel Aviv University Company Overview 160
  • 5.109 The Walter and Eliza Hall Institute of Medical Research Company Overview 161
  • 5.110 TheraDiag SA Company Overview 162
  • 5.111 Treos Bio Inc Company Overview 167
  • 5.112 Trinity College Dublin Company Overview 168
  • 5.113 Universal Diagnostics SL Company Overview 169
  • 5.114 University of Alabama at Birmingham Company Overview 170
  • 5.115 University of Illinois at Chicago Company Overview 173
  • 5.116 University of Lyon Company Overview 174
  • 5.117 University of Michigan Company Overview 175
  • 5.118 University of Notre Dame Company Overview 176
  • 5.119 University of Pittsburgh Company Overview 177
  • 5.120 University of Texas MD Anderson Cancer Center Company Overview 180
  • 5.121 US Biomarkers Inc Company Overview 181
  • 5.122 vall d hebron institut de Recerca Company Overview 182
  • 5.123 Vanderbilt University Company Overview 184
  • 5.124 Viomics Inc. Company Overview 186
  • 5.125 VolitionRX Ltd Company Overview 187
  • 5.126 XEPTAGEN SpA Company Overview 196

6 Colorectal Cancer Diagnostic Tests - Recent Developments 197

  • 6.1 Sep 06, 2017: MDxHealth Prepares for Growth with Executive Team Expansion 197
  • 6.2 Sep 05, 2017: EDP Biotech Received U.S. Patent for CA11-19 Biomarker, Methods and Compositions for Screening and Detecting Colorectal Cancer 197
  • 6.3 Sep 05, 2017: Rosetta Genomics to Reduce Operating and Other Expenses 198
  • 6.4 Aug 31, 2017: Strong performance data of proprietary MSI Biomarkers for the Idylla MSI Test to be published at ESMO 198
  • 6.5 Aug 31, 2017: MDxHealth Announces First Half 2017 Financial Results 199
  • 6.6 Aug 30, 2017: bioMerieux - First-Half 2017 Results 201
  • 6.7 Aug 29, 2017: Todos Medical Appoints Dr. Meir Silver as Vice President of Clinical Research and Regulatory Affairs 205
  • 6.8 Aug 22, 2017: Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers 205
  • 6.9 Aug 17, 2017: Biohit Group Half Year Financial Report 2017 206
  • 6.10 Aug 15, 2017: GeneNews Announces Q2-2017 Financial Results & Provides Progress Update 210
  • 6.11 Aug 14, 2017: PRA Health Sciences Announces Appointment of New Director 211
  • 6.12 Aug 09, 2017: VolitionRx Announces Second Quarter 2017 Financial Results and Business Update 212
  • 6.13 Aug 07, 2017: MDxHealth Appoints Seasoned EVP to Lead Sales Force Expansion 213
  • 6.14 Aug 07, 2017: PRA Health Sciences Reports Second Quarter 2017 Results and Updates Full Year 2017 Guidance 213
  • 6.15 Aug 01, 2017: Genomic Health Announces Second Quarter 2017 Financial Results and Reports Recent Business Progress 215
  • 6.16 Aug 01, 2017: llumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2017 217
  • 6.17 Aug 01, 2017: Illumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2017 218
  • 6.18 Jul 31, 2017: Applied Proteomics Announces Three Additional Data Sets That Further Validate its Linus Technology, a Protein Discovery and Test Delivery Engine 219
  • 6.19 Jul 25, 2017: NeoGenomics Reports Record Revenue of $66.1 Million on 16% Volume Growth and 13% Reduction in Average Cost per Test in the Second Quarter of 2017 220
  • 6.20 Jul 25, 2017: Cologuard revenue increased to $57.6 million during second quarter; Test volume grew 149 percent from second quarter of 2016 to 135,000 completed tests 221
  • 6.21 Jul 25, 2017: Theradiag: Further Strong Sales Growth in the First Half of 2017: +9% 221
  • 6.22 Jul 20, 2017: bioMerieux - Second-Quarter 2017 Business Review 222
  • 6.23 Jul 19, 2017: Volition to host a conference call regarding a 13,500 Subject Colorectal Cancer Screening Trial with the Early Detection Research Network of the U.S. National Cancer Institute 225
  • 6.24 Jul 13, 2017: BioTime Subsidiary AgeX Therapeutics Appoints Aubrey de Grey, Ph.D. as VP of New Technology Discovery 225
  • 6.25 Jul 11, 2017: Integragen Reports Continued Growth During 1st Half Of 2017 226
  • 6.26 Jul 06, 2017: Rosetta Genomics Expands Patent Portfolio in Canada, United States, and China 227
  • 6.27 Jul 06, 2017: Epigenomics issues change in guidance for financial year 2017 227
  • 6.28 Jul 03, 2017: Premaitha Health Litigation Update 227

7 Appendix 353

  • 7.1 Methodology 353
  • 7.2 About GlobalData 356
  • 7.3 Contact Us 356
  • 7.4 Disclaimer 356

List of Tables

1.1 List of Tables

  • Table 1: Colorectal Cancer Diagnostic Tests - Pipeline Products by Stage of Development 21
  • Table 2: Colorectal Cancer Diagnostic Tests - Pipeline Products by Territory 22
  • Table 3: Colorectal Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 23
  • Table 4: Colorectal Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 24
  • Table 5: Colorectal Cancer Diagnostic Tests - Ongoing Clinical Trials 25
  • Table 6: Colorectal Cancer Companies - Pipeline Products by Stage of Development 26
  • Table 7: Colorectal Cancer - Pipeline Products by Stage of Development 31
  • Table 8: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 35
  • Table 9: Diagnostic Assay - Colorectal Cancer - Product Status 35
  • Table 10: Diagnostic Assay - Colorectal Cancer - Product Description 35
  • Table 11: Advanced Marker Discovery SL Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 12: ColoFast - Product Status 36
  • Table 13: ColoFast - Product Description 36
  • Table 14: Advpharma Inc Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 15: Molecular Diagnostic Biomarker - Colorectal Cancer - Product Status 37
  • Table 16: Molecular Diagnostic Biomarker - Colorectal Cancer - Product Description 37
  • Table 17: Almac Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 18: DNA Damage Response Deficiency Assay - Colorectal Cancer - Product Status 38
  • Table 19: DNA Damage Response Deficiency Assay - Colorectal Cancer - Product Description 38
  • Table 20: Ambergen Inc Pipeline Products & Ongoing Clinical Trials Overview 39
  • Table 21: Veracode - Colorectal Cancer - Product Status 39
  • Table 22: Veracode - Colorectal Cancer - Product Description 39
  • Table 23: Applied Proteomics Inc Pipeline Products & Ongoing Clinical Trials Overview 40
  • Table 24: SimpliPro Colon-A - Product Status 40
  • Table 25: SimpliPro Colon-A - Product Description 40
  • Table 26: Arizona State University Pipeline Products & Ongoing Clinical Trials Overview 41
  • Table 27: Biomarker Test - Colorectal Cancer - Product Status 41
  • Table 28: Biomarker Test - Colorectal Cancer - Product Description 41
  • Table 29: ArtemixRx Pipeline Products & Ongoing Clinical Trials Overview 42
  • Table 30: ArtemixRx Prognostic Test - Colon Cancer - Product Status 42
  • Table 31: ArtemixRx Prognostic Test - Colon Cancer - Product Description 42
  • Table 32: Avant Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 43
  • Table 33: TheraLink Assay - Colorectal Cancer - Product Status 43
  • Table 34: TheraLink Assay - Colorectal Cancer - Product Description 43
  • Table 35: Bio Mark Ltd Pipeline Products & Ongoing Clinical Trials Overview 44
  • Table 36: Diagnostic Test - Colorectal Adenoma - Product Status 44
  • Table 37: Diagnostic Test - Colorectal Adenoma - Product Description 44
  • Table 38: Biocartis SA Pipeline Products & Ongoing Clinical Trials Overview 45
  • Table 39: Idylla MSI Test - Product Status 45
  • Table 40: Idylla MSI Test - Product Description 45
  • Table 41: Biodesix Inc Pipeline Products & Ongoing Clinical Trials Overview 46
  • Table 42: VeriStrat - Colorectal Cancer - Product Status 46
  • Table 43: VeriStrat - Colorectal Cancer - Product Description 46
  • Table 44: BioMarCare Technologies Ltd. Pipeline Products & Ongoing Clinical Trials Overview 47
  • Table 45: Colon MarCarePlex - Product Status 47
  • Table 46: Colon MarCarePlex - Product Description 47
  • Table 47: mCRC-Strat - Product Status 48
  • Table 48: mCRC-Strat - Product Description 48
  • Table 49: BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 49
  • Table 50: Metabolomics-based Diagnostic Assay - Colorectal Cancer - Product Status 49
  • Table 51: Metabolomics-based Diagnostic Assay - Colorectal Cancer - Product Description 49
  • Table 52: BioMarker Strategies LLC Pipeline Products & Ongoing Clinical Trials Overview 50
  • Table 53: Ex Vivo Biomarker Test - Colon Cancer - Product Status 50
  • Table 54: Ex Vivo Biomarker Test - Colon Cancer - Product Description 50
  • Table 55: bioMerieux S.A. Pipeline Products & Ongoing Clinical Trials Overview 51
  • Table 56: Diagnostic Test - Colorectal Cancer - Product Status 51
  • Table 57: Diagnostic Test - Colorectal Cancer - Product Description 51
  • Table 58: Biomoda, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 52
  • Table 59: CyPath Diagnostic Assay - Colorectal Cancer - Product Status 52
  • Table 60: CyPath Diagnostic Assay - Colorectal Cancer - Product Description 52
  • Table 61: Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview 53
  • Table 62: MBDAA Colorectal Cancer Test - Product Status 53
  • Table 63: MBDAA Colorectal Cancer Test - Product Description 53
  • Table 64: Biosceptre International Ltd Pipeline Products & Ongoing Clinical Trials Overview 54
  • Table 65: Colorectal Cancer IHC Diagnostic Test - Product Status 54
  • Table 66: Colorectal Cancer IHC Diagnostic Test - Product Description 54
  • Table 67: BioSystems International Pipeline Products & Ongoing Clinical Trials Overview 55
  • Table 68: Diagnostic Test - Colon Cancer - Product Status 55
  • Table 69: Diagnostic Test - Colon Cancer - Product Description 55
  • Table 70: BioTime Inc Pipeline Products & Ongoing Clinical Trials Overview 56
  • Table 71: PanC-Dx - Colon Cancer - Product Status 56
  • Table 72: PanC-Dx - Colon Cancer - Product Description 56
  • Table 73: Biotron Ltd Pipeline Products & Ongoing Clinical Trials Overview 57
  • Table 74: C-Test - Colorectal Cancer - Product Status 57
  • Table 75: C-Test - Colorectal Cancer - Product Description 57
  • Table 76: Castle Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 58
  • Table 77: DecisionDx - Rectal Cancer - Product Status 58
  • Table 78: DecisionDx - Rectal Cancer - Product Description 58
  • Table 79: Catholic University of Leuven Pipeline Products & Ongoing Clinical Trials Overview 59
  • Table 80: Diagnostic Test - Colorectal Cancer - Product Status 59
  • Table 81: Diagnostic Test - Colorectal Cancer - Product Description 59
  • Table 82: Cellmid Ltd Pipeline Products & Ongoing Clinical Trials Overview 60
  • Table 83: MK-ELISA Assay - Colorectal Cancer - Product Status 60
  • Table 84: MK-ELISA Assay - Colorectal Cancer - Product Description 60
  • Table 85: MK-ELISA Assay - Metastatic Colorectal Cancer - Product Status 61
  • Table 86: MK-ELISA Assay - Metastatic Colorectal Cancer - Product Description 61
  • Table 87: Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 62
  • Table 88: Nanotrap Colon Cancer Biomarker Test - Product Status 62
  • Table 89: Nanotrap Colon Cancer Biomarker Test - Product Description 62
  • Table 90: Cernostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 63
  • Table 91: TissueCypher Colon Cancer Test - Product Status 63
  • Table 92: TissueCypher Colon Cancer Test - Product Description 63
  • Table 93: China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 64
  • Table 94: Diagnostic Kit - Rectum Cancer - Product Status 64
  • Table 95: Diagnostic Kit - Rectum Cancer - Product Description 64
  • Table 96: Chinese University of Hong Kong Pipeline Products & Ongoing Clinical Trials Overview 65
  • Table 97: Colorectal Cancer Screening Tool - Product Status 65
  • Table 98: Colorectal Cancer Screening Tool - Product Description 65
  • Table 99: Micro-RNA Based Biomarker Assay - Colon Cancer - Product Status 66
  • Table 100: Micro-RNA Based Biomarker Assay - Colon Cancer - Product Description 66
  • Table 101: Chronix Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 67
  • Table 102: Companion Diagnostic Test - Colorectal Cancer - Product Status 67
  • Table 103: Companion Diagnostic Test - Colorectal Cancer - Product Description 67
  • Table 104: Columbia University Pipeline Products & Ongoing Clinical Trials Overview 68
  • Table 105: IGFBP-3 Diagnostic Test - Product Status 68
  • Table 106: IGFBP-3 Diagnostic Test - Product Description 68
  • Table 107: Courtagen Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 69
  • Table 108: Colorectal Cancer Diagnostic Panel - Product Status 69
  • Table 109: Colorectal Cancer Diagnostic Panel - Product Description 69
  • Table 110: CS-Keys, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 70
  • Table 111: caPCNA - Colorectal Cancer - Product Status 70
  • Table 112: caPCNA - Colorectal Cancer - Product Description 70
  • Table 113: Di.V.A.L Toscana srl Pipeline Products & Ongoing Clinical Trials Overview 71
  • Table 114: NanoMabKv - Colorectal Cancer - Product Status 71
  • Table 115: NanoMabKv - Colorectal Cancer - Product Description 71
  • Table 116: DiagnoCure Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 72
  • Table 117: Colorectal/GCC Monitoring Test - Product Status 72
  • Table 118: Colorectal/GCC Monitoring Test - Product Description 72
  • Table 119: Colorectal/Shc Prognostic Test - Product Status 73
  • Table 120: Colorectal/Shc Prognostic Test - Product Description 73
  • Table 121: Diaxonhit SA Pipeline Products & Ongoing Clinical Trials Overview 74
  • Table 122: EHT Dx 12 - Product Status 74
  • Table 123: EHT Dx 12 - Product Description 74
  • Table 124: Diazyme Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 75
  • Table 125: TRAIL-R2 Assay - Product Status 75
  • Table 126: TRAIL-R2 Assay - Product Description 75
  • Table 127: DNAlytics Pipeline Products & Ongoing Clinical Trials Overview 76
  • Table 128: ColonoKit - Product Status 76
  • Table 129: ColonoKit - Product Description 76
  • Table 130: DNAlytics - Ongoing Clinical Trials Overview 77
  • Table 131: ColonoKit - ColonoKit Clinical Evaluation in Colorectal Cancer Subjects 78
  • Table 132: EDP Biotech Corporation Pipeline Products & Ongoing Clinical Trials Overview 79
  • Table 133: ColoMarker Assay - Product Status 79
  • Table 134: ColoMarker Assay - Product Description 79
  • Table 135: Epigenomics AG Pipeline Products & Ongoing Clinical Trials Overview 80
  • Table 136: Diagnostic Test - Colorectal Cancer - Product Status 80
  • Table 137: Diagnostic Test - Colorectal Cancer - Product Description 81
  • Table 138: Epi proColon 1.0 - Product Status 81
  • Table 139: Epi proColon 1.0 - Product Description 81
  • Table 140: Eventus Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 82
  • Table 141: Octava Test - Colon Cancer - Product Status 82
  • Table 142: Octava Test - Colon Cancer - Product Description 82
  • Table 143: Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 83
  • Table 144: PreGen-Plus - Product Status 83
  • Table 145: PreGen-Plus - Product Description 83
  • Table 146: Exiqon A/S Pipeline Products & Ongoing Clinical Trials Overview 84
  • Table 147: Colon Cancer Test - Stage III And IV Patient - Product Status 84
  • Table 148: Colon Cancer Test - Stage III And IV Patient - Product Description 84
  • Table 149: Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview 85
  • Table 150: ExoTEST Colorectal - Product Status 85
  • Table 151: ExoTEST Colorectal - Product Description 85
  • Table 152: Fina Biotech SL Pipeline Products & Ongoing Clinical Trials Overview 86
  • Table 153: Dx Bioenergetic Signature - Colon Cancer - Product Status 86
  • Table 154: Dx Bioenergetic Signature - Colon Cancer - Product Description 86
  • Table 155: GenomicTree Inc Pipeline Products & Ongoing Clinical Trials Overview 87
  • Table 156: EarlyTect Colon Cancer - Product Status 87
  • Table 157: EarlyTect Colon Cancer - Product Description 87
  • Table 158: EarlyTect Colorectal Cancer - Recurrence - Product Status 88
  • Table 159: EarlyTect Colorectal Cancer - Recurrence - Product Description 88
  • Table 160: GenomicTree Inc - Ongoing Clinical Trials Overview 89
  • Table 161: EarlyTect Colon Cancer - Clinical Study for the Validation of Real Time qPCR for SDC2 Methylation in Stool DNA for Early Detection of Colorectal Cancer 90
  • Table 162: German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 91
  • Table 163: Autoantibody Panel - Colorectal Cancer - Product Status 91
  • Table 164: Autoantibody Panel - Colorectal Cancer - Product Description 91
  • Table 165: Biomarker Panel - Colorectal Cancer - Product Status 92
  • Table 166: Biomarker Panel - Colorectal Cancer - Product Description 92
  • Table 167: Ghent University Pipeline Products & Ongoing Clinical Trials Overview 93

List of Figures

1.2 List of Figures

  • Figure 1: Colorectal Cancer Diagnostic Tests - Pipeline Products by Stage of Development 21
  • Figure 2: Colorectal Cancer Diagnostic Tests - Pipeline Products by Territory 22
  • Figure 3: Colorectal Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 23
  • Figure 4: Colorectal Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 24
  • Figure 5: Colorectal Cancer Diagnostic Tests - Ongoing Clinical Trials 25
Back to Top